Patient-derived Ovarian Cancer Explants: Preserved Viability and Histopathological Features in Long-Term Agitation-Based Cultures
Open accessAbstract
Ovarian carcinoma (OvC) remains a major therapeutic challenge due to its propensity to develop resistance after an initial response to chemotherapy. Interactions of tumour cells with the surrounding microenvironment play a role in tumour survival, invasion capacity and drug resistance. Cancer models that retain tissue architecture and tumour microenvironment components are therefore essential to understand drug response and resistance mechanisms. Herein, our goal was to develop a long-term OvC patient-derived explant (OvC-PDE) culture strategy in which architecture and cell type heterogeneity of the original tumour would be retained. Samples from 25 patients with distinct OvC types and one with a benign tumour, were cultured for 30 days in agitation-based culture systems with 100% success rate. OvC-PDE cultures retained the original tumour architecture and main cellular components: epithelial cells, fibroblasts and immune cells. Epithelial cells kept their original levels of proliferation and apoptosis. Moreover, the major extracellular components, such as collagen-I and -IV, were retained in explants. OvC-PDE cultures were exposed to standard-of-care chemotherapeutics agents for 2 weeks, attesting the ability of the platform for drug assays employing cyclic drug exposure regimens. We established an OvC-PDE dynamic culture in which tumour architecture and cell type heterogeneity were preserved for the different OvC types, replicating features of the original tumour and compatible with long-term drug exposure for drug efficacy and resistance studies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patient-derived explants of multiple ovarian cancer histotypes have been propagated for up to 30 days in orbital shakers, resulting in maintenance of tumor architectures, epithelial, fibroblasts and immune cells, as well as ECM.
“Patient-derived explants of multiple ovarian cancer histotypes have been propagated for up to 30 days in orbital shakers, resulting in maintenance of tumor architectures, epithelial, fibroblasts and immune cells, as well as ECM (Abreu et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Abreu et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,811 · see citing works
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · see citing works
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149 · see citing works
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · see citing works
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362 · see citing works
Pitt, J. M., Marabelle, A., Eggermont, A. M. M., Soria, J., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,344 · see citing works
Three-dimensional cell culture: the missing link in drug discovery
Breslin, S., & O’Driscoll, L. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.003 · Cited by 1,332 · see citing works
Applied Biopharmaceutics and Pharmacokinetics.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-6-826_2 · Cited by 1,212 · see citing works
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834 · see citing works
Three-dimensional tissue culture models in cancer biology
Kim, J. B. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.05.002 · Cited by 613 · see citing works
Impact of the physical microenvironment on tumor progression and metastasis
Spill, F., Reynolds, D. S., Kamm, R. D., & Zaman, M. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.007 · Cited by 582 · see citing works
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525 · see citing works
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452 · see citing works
Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., McNamara, K. L., Sandoval, J. L., Cassidy, J. W., Vidaković, A. T., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.041 · Cited by 432 · see citing works
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 423 · see citing works
Legrand-Frossi, C., Bour, J. M., Jacob, C., Capiaumont, J., Martial, A., Marc, A., Wudtke, M., Kretzmer, G., Demangel, C., Duval, D., et al. (1992) · Journal of Biotechnology · doi:10.1016/0168-1656(92)90158-6 · Cited by 403 · see citing works
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 400 · see citing works
A systematic review of geographical variation in access to chemotherapy
Chamberlain, C., Owen‐Smith, A., Donovan, J., & Hollingworth, W. (2015) · BMC Cancer · doi:10.1186/s12885-015-2026-y · Cited by 392 · see citing works
Integrin-mediated Cell Adhesion to Type I Collagen Fibrils
Jokinen, J., Dadu, E., Nykvist, P., Käpylä, J., White, D. J., Ivaska, J., Vehviläinen, P., Reunanen, H., Larjava, H., Häkkinen, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401409200 · Cited by 380 · see citing works
Hickman, J. A., Graeser, R., Hoogt, R. D., Vidic, S., Brito, C., Gutekunst, M., & van der Kuip, H. (2014) · Biotechnology Journal · doi:10.1002/biot.201300492 · Cited by 379 · see citing works
Self-citationRuggeri, B., Camp, F., & Miknyoczki, S. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.020 · Cited by 369 · see citing works
Julien-Grille, S., Merino‐Trigo, A., Lacroix, L., Pocard, M. D., Goèré, D., Mariani, P., Landron, S., Bigot, L., Némati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 358 · see citing works
He, S., Liu, Z., Oh, D., & Thiele, C. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00001 · Cited by 327 · see citing works
Majumder, B., Ulaganathan, B., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., Dhandapani, M., Brijwani, N., Pinto, D. D., Prasath, A., Shanthappa, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms7169 · Cited by 307 · see citing works
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D., Snyder, E. L., Faversani, A., Coggi, G., Flavin, R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907676107 · Cited by 269 · see citing works
Clinical Pharmacokinetics of Carboplatin
van der Vijgh, W. J. F. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121040-00002 · Cited by 263 · see citing works
Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., Barbier, M., Blom, S., Arundkar, S. C., Selvam, I., et al. (2016) · Scientific Reports · doi:10.1038/srep28951 · Cited by 253 · see citing works
Self-citationSodek, K. L., Ringuette, M. J., & Brown, T. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24188 · Cited by 248 · see citing works
Recent Concepts of Ovarian Carcinogenesis: Type I and Type II
Koshiyama, M., Matsumura, N., & Konishi, I. (2014) · BioMed Research International · doi:10.1155/2014/934261 · Cited by 242 · see citing works
3D-3-culture: a tool to unveil macrophage plasticity in the tumour microenvironment
Rebelo, S. P., Pinto, C., Martins, T. R., Harrer, N., Estrada, M. F., Loza-Alvarez, P., Cabeçadas, J., Alves, P. M., Gualda, E. J., Sommergruber, W., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.030 · Cited by 227 · see citing works
Self-citationEpithelial ovarian cancer experimental models
Lengyel, E. R., Burdette, J. E., Kenny, H. A., Matei, D. E., Pilrose, J. M., Haluska, P., Nephew, K. P., Hales, D. B., & Stack, M. S. (2013) · Oncogene · doi:10.1038/onc.2013.321 · Cited by 209 · see citing works
Tumor microenvironment: The culprit for ovarian cancer metastasis?
Luo, Z., Wang, Q., Lau, W. B., Lau, B., Xu, L., Zhao, L., Yang, H., Feng, M., Yu, X., Yang, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.038 · Cited by 191 · see citing works
Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Weroha, S. J., Becker, M. A., Enderica-Gonzalez, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2611 · Cited by 189 · see citing works
Hofmann, G., Bauernhofer, T., Krippl, P., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-1 · Cited by 182 · see citing works
Advanced health biotechnologies in Thailand: redefining policy directions
Velasco, R. P., Chaikledkaew, U., Myint, C. Y., Khampang, R., Tantivess, S., & Teerawattananon, Y. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-1 · Cited by 182 · see citing works
Thibault, B., Castells, M., Delord, J., & Couderc, B. C. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9456-2 · Cited by 181 · see citing works
Ex Vivo Tumor Culture Systems for Functional Drug Testing and Therapy Response Prediction
Meijer, T. G., Naipal, K. A. T., Jager, A., & van Gent, D. C. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0003 · Cited by 166 · see citing works
Reverse Genetics Approaches for the Development of Influenza Vaccines
Nogales, A., & Martínez‐Sobrido, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010020 · Cited by 164 · see citing works
Tumor slice culture system to assess drug response of primary breast cancer
Naipal, K. A. T., Verkaik, N. S., Sánchez, H., van Deurzen, C. H. M., den Bakker, M. A., Hoeijmakers, J. H. J., Kanaar, R., Vreeswijk, M. P. G., Jager, A., & van Gent, D. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2119-2 · Cited by 156 · see citing works
Schauer, I. G., Sood, A. K., Mok, S. C., & Liu, J. (2011) · Neoplasia · doi:10.1593/neo.101720 · Cited by 155 · see citing works
The Extracellular Matrix in Epithelial Ovarian Cancer – A Piece of a Puzzle
Cho, A., Howell, V. M., & Colvin, E. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00245 · Cited by 132 · see citing works
Extracellular Matrix of Ovarian Tumors
Ricciardelli, C., & Rodgers, R. J. (2006) · Seminars in Reproductive Medicine · doi:10.1055/s-2006-948556 · Cited by 125 · see citing works
Davies, E. J., Dong, M., Gutekunst, M., Närhi, K. M., Zoggel, H. J. A. A. V., Blom, S., Nagaraj, A. S., Metsalu, T., Oswald, E., Erkens‐Schulze, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17187 · Cited by 122 · see citing works
Targeting the tumour microenvironment in ovarian cancer
Hansen, J. M., Coleman, R. L., & Sood, A. K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.016 · Cited by 122 · see citing works
Subtypes of Ovarian Cancer and Ovarian Cancer Screening
Koshiyama, M., Matsumura, N., & Konishi, I. (2017) · Diagnostics · doi:10.3390/diagnostics7010012 · Cited by 120 · see citing works
Santo, V. E., Estrada, M. F., Rebelo, S. P., Abreu, S. C., Silva, I., Pinto, C., Veloso, S. C., Serra, T., Boghaert, E. R., Alves, P. M., et al. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.01.031 · Cited by 118 · see citing works
Self-citationCheteh, E. H., Augsten, M., Rundqvist, H., Bianchi, J., Sarne, V., Egevad, L., Bykov, V. J. N., Östman, A., & Wiman, K. G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.225 · Cited by 118 · see citing works
Estrada, M. F., Rebelo, S. P., Davies, E. J., Pinto, M. T., Pereira, H., Santo, V. E., Smalley, M. J., Barry, S. T., Gualda, E. J., Alves, P. M., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.030 · Cited by 113 · see citing works
Self-citationvan der Kuip, H., Mürdter, T. E., Sonnenberg, M., McClellan, M., Gutzeit, S., Gerteis, A., Simon, W. E., Fritz, P., & Aulitzky, W. E. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-86 · Cited by 110 · see citing works
Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer
Chen, K., Gentry‐Maharaj, A., Burnell, M., Steentoft, C., Marcos-Silva, L., Mandel, U., Jacobs, I. J., Dawnay, A., Menon, U., & Blixt, O. (2013) · Journal of Proteome Research · doi:10.1021/pr3010474 · Cited by 107 · see citing works
Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure
von Strandmann, E. P., Reinartz, S., Wager, U., & Müller, R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.12.005 · Cited by 102 · see citing works
Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00295 · Cited by 100 · see citing works
Boyd, V., Cholewa, O. M., & Papas, K. K. (2008) · PubMed · Cited by 95 · see citing works
Karekla, E., Liao, W., Sharp, B. L., Pugh, J., Reid, H. J., Quesne, J. P. C. L., Moore, D. A., Pritchard, C. A., MacFarlane, M., & Pringle, J. H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1121 · Cited by 90 · see citing works
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 88 · see citing works
Thuwajit, C., Ferraresi, A., Titone, R., Thuwajit, P., & Isidoro, C. (2017) · Medicinal Research Reviews · doi:10.1002/med.21473 · Cited by 84 · see citing works
Origin of the vasculature supporting growth of primary patient tumor xenografts
Hylander, B. L., Punt, N., Tang, H., Hillman, J. C., Vaughan, M. M., Bshara, W., Pitoniak, R., & Repasky, E. A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-110 · Cited by 81 · see citing works
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Heo, E. J., Cho, Y., Cho, W. C. S., Hong, J. E., Jeon, H., Oh, D., Choi, Y., Song, S. Y., Choi, J., Bae, D., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.322 · Cited by 70 · see citing works
Skubitz, A. P. N., Bast, R. C., Wayner, E. A., et al. (1996) · PubMed · Cited by 65 · see citing works
Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer
Chen, Y., Zhang, L., Liu, W., & Liu, X. (2015) · BioMed Research International · doi:10.1155/2015/589301 · Cited by 65 · see citing works
Sonnaert, M., Papantoniou, I., Luyten, F. P., et al. (2014) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2014.0255 · Cited by 60 · see citing works
Lopes‐Coelho, F., Gouveia-Fernandes, S., Gonçalves, L. G., Nunes, C., Faustino, I., SILVA, F. A. B. N. D., Félix, A., Pereira, S. A., & Serpa, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4290-5 · Cited by 57 · see citing works
Self-citationAlkema, N. G., Tomar, T., Duiker, E. W., Meersma, G. J., Klip, H. G., van der Zee, A. G. J., Wisman, G. B. A., & de Jong, S. (2015) · Scientific Reports · doi:10.1038/srep14495 · Cited by 54 · see citing works
Dong, R., Qiang, W., Guo, H., Xu, X., Kim, J. J., Mazar, A., Kong, B., & Wei, J.-J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0318-6 · Cited by 49 · see citing works
Torres, I. E. C., Guzmán‐Delgado, N. E., Coronado-Martínez, C., Bañuelos-García, J. I., Viveros‐Valdez, E., Morán‐Martínez, J., & Carranza‐Rosales, P. (2015) · BioMed Research International · doi:10.1155/2015/618021 · Cited by 46 · see citing works
Ricciardelli, C., Lokman, N. A., Sabit, I., Gunasegaran, K., Bonner, W. M., Pyragius, C. E., Macpherson, A. M., & Oehler, M. K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.006 · Cited by 46 · see citing works
The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer
Carrillo, M. A., Zhen, A., & Kitchen, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00746 · Cited by 46 · see citing works
Kageyama, K., Ohara, M., Saito, K., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1247-z · Cited by 44 · see citing works
The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac, L., Carcangiu, M. L., Canevari, S., et al. (2013) · PubMed · Cited by 43 · see citing works
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
Hirsh, V., Pignata, S., Bersanelli, M., Gnetti, L., Azzoni, C., Bottarelli, L., Gasparro, D., Leonardi, F., Silini, E. M., Buti, S., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1095-2 · Cited by 43 · see citing works
When Is “Type I” Ovarian Cancer Not “Type I”? Indications of an Out-Dated Dichotomy
Salazar, C., Campbell, I., & Gorringe, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00654 · Cited by 42 · see citing works
Chao, C., Widen, S. G., Wood, T. G., Zatarain, J. R., Johnson, P. R., Gajjar, A. H., GOMEZ, G., Qiu, S., Thompson, J. C., Spratt, H. M., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11707 · Cited by 39 · see citing works
Drew, A. F., Blick, T., Lafleur, M. A., et al. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.032 · Cited by 32 · see citing works
Parajuli, N., & Doppler, W. (2009) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-009-9212-7 · Cited by 28 · see citing works
Niclosamide Analogs for Treatment of Ovarian Cancer
Haygood, C. L. W., Arend, R. C., Gangrade, A., Chettiar, S. N., Regan, N., Hassmann, C. J., Li, P., Hidalgo, B., Straughn, J. M., & Buchsbaum, D. J. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000506 · Cited by 26 · see citing works
Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance
Chan, M. X. L. D. W., & Ngan, H. (2012) · Gynecology & Obstetrics · doi:10.4172/2161-0932.1000e104 · Cited by 26 · see citing works
Sun, W., & Fu, S. (2019) · Oncology Letters · doi:10.3892/ol.2019.10587 · Cited by 25 · see citing works
Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units
Siu, L. L., Attardo, G. G., Izbicka, E., Lawrence, R., Cerna, C., Gomez, L., Davidson, K. K., Finkle, C. D., Marsolais, C., Rowinsky, E. K., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008387019062 · Cited by 24 · see citing works
Pennington, K., Chu, Q. D., Curiel, D. T., et al. (2010) · Journal of Surgical Research · doi:10.1016/j.jss.2010.03.072 · Cited by 19 · see citing works
Tumor Microenvironment in Human Tumor Xenografted Mouse Models
Varna, M., Bertheau, P., & Legrès, L. (2014) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2014.03.03.6 · Cited by 15 · see citing works
Precision Cut Cancer Tissue Slices in Anti-Cancer Drug Testing
Unger, F. T., Bentz, S., Krüger, J., et al. (2015) · Journal of Molecular Pathophysiology · doi:10.5455/jmp.20151023055556 · Cited by 15 · see citing works
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
Pu, X., Zhang, R., Wang, L., Chen, Y., Xu, Y., Pataer, A., Meraz, I. M., Zhang, X., Wu, S., Wu, L., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1704-3 · Cited by 15 · see citing works
Generation of improved mouse models for the study of hepatitis C virus
Douglas, D. N., & Kneteman, N. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.022 · Cited by 13 · see citing works
Mita, C., Chatelut, É., Békradda, M., Soulié, P., Canal, P., Misset, J. L., Cvitkovic, E., & Bugat, R. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg490 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works
Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models
Cox, M. C., Mendes, R., Silva, F., Mendes, T. F., Zelaya-Lazo, A., Halwachs, K., Purkal, J. J., Isidro, I. A., Félix, A., Boghaert, E. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97894-0 · Cited by 58 · see citing works
Self-citationBoghaert, E. R., Cox, M. C., & Vaidya, K. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3236 · Cited by 17 · see citing works
Self-citation
- Authors
- Abreu, S., Silva, F., Mendes, R., Mendes, T. F., Teixeira, M., Santo, V. E., Boghaert, E. R., Félix, A., & Brito, C.
- Affiliations
- Instituto de Biologia Experimental e Tecnológica (PT)
- Universidade Nova de Lisboa (PT)
- AbbVie (United States) (US)
- Instituto Português de Oncologia Francisco Gentil (PT)
- Corresponding author
- Brito, Catarina
- ORCID
- Venue
- Scientific Reports
- Published
- 2020-11-10
- Volume
- 10
- Issue
- 1
- Pages
- 19462-19462
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7655823
- OpenAlex
- W3102039662
- Cited by
- 31
- References
- 84
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 5
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education and Science |Fundação para a Ciência e a Tecnologia (PD/BD/105768/2014, SFRH/BD/132163/2017, UIDB/04462/2020)
- AbbVie
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- ovarian cancer, patient-derived explants, tumor microenvironment, tumor architecture, cellular heterogeneity, drug resistance, chemotherapy efficacy, extracellular matrix, collagen, fibroblasts, immune cells, dynamic culture
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Cell Survival, Epithelial Cells, Female, Fibroblasts, Humans, Middle Aged, Ovarian Neoplasms, Time Factors, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, Cell Culture Techniques, Ki-67 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
